Copper, Collagen, and Beyond: Which Skincare Peptides Actually Have Evidence?

The claim is that a skincare product labeled with the word peptide delivers proven anti-aging results. This review did not find a company stating it in exactly those words. It sits in the gap between an ingredient name and a promise. One current example is rhode skin's Peptide Lip Treatment page, whose footer reads © 2026. The page says the product “smooths fine lines on the lips and visibly plumps lips over time” and lists palmitoyl tripeptide-1 among its ingredients.¹³

The record does not support the claim. Under U.S. law, cosmetics and their ingredients, other than color additives, do not need FDA premarket approval, and the statute and FDA pages reviewed do not define peptide as a product category.³,²,⁶ The clinical evidence comes one peptide at a time. Much of it is small and short, and one review discussed here was written in part by an author employed part-time by Espikem Srl, a company the paper does not describe.¹⁰,¹¹,¹²

What does peptide mean under the law?

The statute and the FDA pages reviewed here do not say. The Federal Food, Drug, and Cosmetic Act defines a cosmetic as an article applied to the body “for cleansing, beautifying, promoting attractiveness, or altering the appearance.”⁶ The FDA says a product can be a drug, a cosmetic, or both, “but the term ‘cosmeceutical’ has no meaning under the law.”² Neither source treats peptide as a category of product. On a label, it names an ingredient. It does not report a result.

Did FDA have to check the claim?

No. The FDA states that “cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives.”³ Its labeling page adds that the agency “does not have a list of approved or accepted claims for cosmetics.”⁴ A cosmetic sold as a peptide product is not required to go through FDA premarket review of whether it works.³

The line the agency does draw concerns intent. On a consumer page current as of February 25, 2022, the FDA says a product intended “to remove wrinkles or increase the skin’s production of collagen” is a drug or a medical device.¹ That page is guidance, not a rule, and it does not mention peptides.¹ Drugs face a different standard. In Import Alert 66-41, revised May 19, 2026, the agency says unapproved new drugs “have not been reviewed by FDA for safety or effectiveness.”⁵ In this review's reading, the rhode copy stays on the appearance side of that line. FDA has not assessed this product page, and intended use, not word choice alone, decides the category. It says “smooths” and “visibly plumps,” not “removes” or “builds collagen.”¹³

Who holds an anti-aging claim to a standard?

The Federal Trade Commission, in advertising. On June 30, 2014, it announced a proposed settlement with L’Oréal, subject to public comment and final approval. Its complaint alleged that the company made “false and unsubstantiated claims” that Génifique and Youth Code provided anti-aging benefits by targeting genes.⁷ The staff analysis of the proposed order defined the evidence L’Oréal would need for its gene claims as “evidence, consisting of tests, analyses, research, or studies that have been conducted and evaluated in an objective manner by qualified persons and are generally accepted in the profession to yield accurate and reliable results.”⁸ That case concerned gene-targeting claims, not peptides. The analysis is staff commentary on a proposed order, not the final order.⁸

This review did not search the National Advertising Division, the UK Advertising Standards Authority or the EU Scientific Committee on Consumer Safety, so it makes no statement about their rulings. This review could not open FDA's warning-letter roundup and so cannot say whether a warning letter aimed at a cosmetic peptide claim exists.⁴

What does the record show for copper peptide?

More than for most peptides, and less than the marketing implies. A 2017 review in Cosmetics by Silke Schagen of Beldio Research GmbH reports positive findings for copper tripeptide. These include 12-week studies in 41 and 71 women.¹¹ Those studies were not re-examined for this piece. The same review limits its own conclusions. It says that some of the clinical studies it covers used formulations with other actives and “did not differentiate the role of the mentioned peptide specifically with other actives in the formulation,” so “the observed results cannot be claimed clearly to be the effect of the used peptide.”¹¹ The review does not say which studies, or whether the copper studies are among them.¹¹

A 2024 review in BioImpacts is more critical in its abstract than in its body. Its abstract says that GHK-Cu and Pal-GHK have attracted interest as anti-wrinkle ingredients, yet “there is a surprising absence of clinical studies using them.”⁹ Its body text cites the same 12-week GHK-Cu studies in 41 and 71 women and says it found no clinical or cellular anti-wrinkle studies of Pal-GHK.⁹ It also reports that GHK has poor skin-permeability properties and that “no studies have been published on the possible side effects.”⁹ Its conclusion still calls both peptides effective. For Pal-GHK, that conclusion sits uneasily with the review's own statement that it found no clinical studies.⁹

What happened when two peptides faced a placebo?

Neither showed a statistically significant effect on the instruments. In February 2023, the Journal of Clinical and Aesthetic Dermatology published a double-blind, randomized trial of creams applied to crow's feet. One arm used acetylhexapeptide-3, one used palmitoyl pentapeptide-4 and one used a placebo.¹⁰ The trial enrolled 21 Indonesian women, 7 per arm, for 8 weeks.¹⁰ Corneometer, tewameter and cutometer readings showed no statistically significant effect.¹⁰ The crow's feet grading p-values were 0.611 for acetylhexapeptide-3, 1.000 for palmitoyl pentapeptide-4 and 0.635 for placebo. The placebo arm's static grading score fell from 2.42 to 1.42.¹⁰ Those p-values track each arm against itself over time. For the instrument and grading data, the paper reports no head-to-head test of either cream against placebo. With 7 women per arm, a non-significant result does not show that the creams had no effect.¹⁰ The authors still concluded that palmitoyl pentapeptide-4 did better than the other creams, and said a larger, longer study is needed.¹⁰

The paper says the study was financially supported by Paragon Technology and Innovation in Indonesia, which it does not describe. The authors report no conflicts of interest.¹⁰ The authors call it an initial study. They offer their own explanation: “The insignificant p-value could be caused by the small number of samples, the short duration of the study, and the difference in tool sensitivity.”¹⁰ The trial tested two named peptides in a cream. It did not test peptide serums as a class.

What about the peptide on the rhode label?

The reviewers disagree about it. The rhode page lists palmitoyl tripeptide-1, which the BioImpacts review discusses as Pal-GHK.¹³,⁹ That review says it found no clinical studies of Pal-GHK. The Schagen review reports small studies of palmitoyl tripeptide-1.⁹,¹¹ At best, the published support is thin.

The product page gives no concentration. Its only cited study is a “32-subject consumer perception study after immediate use.” The page also shows an undocumented “Day 1” and “4 Weeks” before-and-after image. The published percentages concern dryness, glide, nourishment and softness, not fine lines or plumping.¹³ That is a record of self-reported agreement. The page publishes four summary percentages but no protocol or underlying data.¹³ The product is also a lip treatment, not a serum.

Do the lesser-known peptides fare better?

The record is thinner, and the reviews conflict. A 2020 mini-review in Frontiers in Chemistry says: “To the best of our knowledge, until now there are no scientific papers describing clinical studies or modifications of Tripeptide-3.”¹² The Schagen review cites a three-month, 37-volunteer study of a tripeptide-3 formulation.¹¹ The Frontiers review relies on manufacturer data for several peptides. One of its authors was employed part-time by Espikem Srl, a company the paper does not describe.¹²

What is missing from the record?

A test of the claim itself. This review did not locate a controlled trial of a named commercial peptide serum against its own vehicle. The Schagen review describes serum-type studies of a manganese tripeptide complex and of a multi-ingredient product with palmitoyl tripeptide-38.¹¹ The studies that exist test named peptides, often in creams, often combined with other actives, and mostly in groups of under 100 people. The largest cited here has 93 subjects.¹⁰,¹¹ Laboratory findings about collagen are not clinical results on wrinkles. A study of one peptide says nothing about another.